Welcome to OncologyPRO, the home of Esmo’s educational and scientific resources.

Phase III data suggest that combining copanlisib with rituximab could be an option for patients with indolent non-Hodgkin lymphoma who have progressed on at least one prior rituximab-based therapy

 Patients with relapsed or refractory B-cell lymphomas may benefit from treatment with bispecific CAR T-cell therapy directed against CD19 and CD20 

Neoadjuvant nivolumab plus chemotherapy could be an option for individuals with early-stage, resectable non-small-cell lung cancer

Early results indicate a modified herpes simplex virus type 1 oncolytic virotherapy may offer a novel treatment for recurrent or progressing high-grade glioma in children

The BNT162b2 mRNA vaccine has a similar profile of short-term side effects for cancer patients undergoing immune checkpoint inhibitor therapy and healthy individuals

The RATIONALE 307 results suggest use of tislelizumab alongside chemotherapy can prolong progression-free survival for treatment-naïve, advanced squamous non-small-cell lung cancer

Phase III trial findings indicate a survival advantage for advanced biliary tract patients who receive second-line FOLFOX chemotherapy alongside active symptom control 

Chronic immune-related adverse events associated with immune checkpoint inhibitor therapy may be more common than previously thought among advanced melanoma patients